Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NCOA1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NCOA1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NCOA1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NCOA1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NCOA1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NCOA1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NCOA1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NCOA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NCOA1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NCOA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NCOA1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166932 | Oral cavity | NEOLP | cellular response to nutrient levels | 42/2005 | 215/18723 | 8.37e-05 | 1.05e-03 | 42 |
GO:00485686 | Oral cavity | NEOLP | embryonic organ development | 71/2005 | 427/18723 | 1.12e-04 | 1.34e-03 | 71 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
GO:006071131 | Oral cavity | NEOLP | labyrinthine layer development | 14/2005 | 44/18723 | 1.28e-04 | 1.49e-03 | 14 |
GO:006066921 | Oral cavity | NEOLP | embryonic placenta morphogenesis | 10/2005 | 26/18723 | 2.04e-04 | 2.19e-03 | 10 |
GO:006071322 | Oral cavity | NEOLP | labyrinthine layer morphogenesis | 9/2005 | 22/18723 | 2.46e-04 | 2.54e-03 | 9 |
GO:190165432 | Oral cavity | NEOLP | response to ketone | 37/2005 | 194/18723 | 3.52e-04 | 3.38e-03 | 37 |
GO:000758423 | Oral cavity | NEOLP | response to nutrient | 33/2005 | 174/18723 | 7.89e-04 | 6.27e-03 | 33 |
GO:000941024 | Oral cavity | NEOLP | response to xenobiotic stimulus | 71/2005 | 462/18723 | 1.12e-03 | 8.45e-03 | 71 |
GO:003235531 | Oral cavity | NEOLP | response to estradiol | 27/2005 | 141/18723 | 1.95e-03 | 1.32e-02 | 27 |
GO:000975515 | Oral cavity | NEOLP | hormone-mediated signaling pathway | 33/2005 | 190/18723 | 3.53e-03 | 2.07e-02 | 33 |
GO:004354331 | Oral cavity | NEOLP | protein acylation | 40/2005 | 243/18723 | 3.85e-03 | 2.21e-02 | 40 |
GO:000647331 | Oral cavity | NEOLP | protein acetylation | 34/2005 | 201/18723 | 4.76e-03 | 2.61e-02 | 34 |
GO:00215371 | Oral cavity | NEOLP | telencephalon development | 40/2005 | 248/18723 | 5.50e-03 | 2.93e-02 | 40 |
GO:001839431 | Oral cavity | NEOLP | peptidyl-lysine acetylation | 29/2005 | 169/18723 | 7.09e-03 | 3.60e-02 | 29 |
GO:002198721 | Oral cavity | NEOLP | cerebral cortex development | 21/2005 | 114/18723 | 9.16e-03 | 4.37e-02 | 21 |
GO:001839331 | Oral cavity | NEOLP | internal peptidyl-lysine acetylation | 27/2005 | 158/18723 | 9.64e-03 | 4.54e-02 | 27 |
GO:00439673 | Oral cavity | NEOLP | histone H4 acetylation | 14/2005 | 67/18723 | 1.04e-02 | 4.87e-02 | 14 |
GO:001657331 | Oral cavity | NEOLP | histone acetylation | 26/2005 | 152/18723 | 1.08e-02 | 4.99e-02 | 26 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa052241 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049192 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049196 | Colorectum | MSI-H | Thyroid hormone signaling pathway | 21/797 | 121/8465 | 4.18e-03 | 4.10e-02 | 3.44e-02 | 21 |
hsa049197 | Colorectum | MSI-H | Thyroid hormone signaling pathway | 21/797 | 121/8465 | 4.18e-03 | 4.10e-02 | 3.44e-02 | 21 |
hsa049198 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa049199 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCOA1 | SNV | Missense_Mutation | | c.2923N>A | p.Pro975Thr | p.P975T | Q15788 | protein_coding | tolerated(0.06) | possibly_damaging(0.766) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
NCOA1 | SNV | Missense_Mutation | novel | c.3535N>C | p.Thr1179Pro | p.T1179P | Q15788 | protein_coding | tolerated(0.2) | benign(0.269) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
NCOA1 | SNV | Missense_Mutation | | c.258N>C | p.Glu86Asp | p.E86D | Q15788 | protein_coding | tolerated(0.43) | benign(0.105) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCOA1 | SNV | Missense_Mutation | novel | c.1729N>A | p.Pro577Thr | p.P577T | Q15788 | protein_coding | tolerated(0.08) | probably_damaging(0.941) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | | c.483N>A | p.His161Gln | p.H161Q | Q15788 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | novel | c.1256A>C | p.Asn419Thr | p.N419T | Q15788 | protein_coding | tolerated(0.14) | benign(0.201) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | | c.4321G>A | p.Glu1441Lys | p.E1441K | Q15788 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NCOA1 | SNV | Missense_Mutation | | c.3938N>G | p.Asn1313Ser | p.N1313S | Q15788 | protein_coding | tolerated(0.2) | possibly_damaging(0.86) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
NCOA1 | SNV | Missense_Mutation | novel | c.2646N>T | p.Gln882His | p.Q882H | Q15788 | protein_coding | deleterious(0.05) | possibly_damaging(0.601) | TCGA-OL-A5D8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA1 | insertion | Nonsense_Mutation | novel | c.1730_1731insTTAAATTATTTGTATTAGGGAGACAAGGGAAG | p.Ala578Ter | p.A578* | Q15788 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | TCMDC-123764 | CHEMBL533226 | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | ETOPOSIDE | ETOPOSIDE | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | inhibitor | 252827441 | | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | METHYLTHIONINIUM CHLORIDE | METHYLTHIONINIUM CHLORIDE | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | tamoxifen | TAMOXIFEN | 22174377 |